2015-06-01T11:39:31-05:00 2014-12-31 582676261 Rogers & Company PLLC 8300 Boone Boulevard Suite 600 Vienna VA 22182 990 2014-01-01 061389829 Albert B Sabin Vaccine Institute Inc ALBE 2028428610 2000 Pennsylvania Avenue NW No 7100 Washington DC 20006 Michael W Marine Chief Executive Officer 2028428610 2015-06-01 1 Nicole M Prince CPA P01315245 7038930300 2015-05-28 2014 2016-02-25 16:41:14Z Michael W Marine 2000 Pennsylvania Avenue NW No 7100 Washington DC 20006 19028714 0 X www.sabin.org X 1994 MD An organization of scientists, researchers and advocates for a world free of needless suffering. 10 8 70 0 0 0 19979693 18983738 2700 16450 37134 28526 0 0 20019527 19028714 8369423 4593597 0 0 5297658 4790957 27164 0 257793 8803203 10023444 22497448 19407998 -2477921 -379284 24430269 23927533 2577813 2454361 21852456 21473172 X To reduce needless human suffering from vaccine-preventable and neglected tropical diseases (NTDs) by developing new vaccines, advocating for increased use of existing vaccines, and promoting expanded access to affordable medical treatments. 0 0 8473080 3274692 Sabin Vaccine Insitute Product Development Partnership (Sabin PDP)With 15 years of research and development experience, the Sabin PDP has created a comprehensive, low-cost model for vaccine development that is a critical component of global efforts to prevent diseases that infect more than one billion people worldwide.Hookworm: The Sabin PDP is currently the only group developing a vaccine for human hookworm disease, an intestinal worm infection that infects more than 440 million people, causing anemia, protein malnutrition and iron-deficiency. The Sabin PDP has two hookworm vaccine candidates currently in development. Both candidates are undergoing Phase 1 clinical testing in Brazil, Gabon and the United States. The Sabin PDP is also conducting an antigen discovery project to determine if additional or alternative recombinant antigens are viable candidates for a human hookworm vaccine.Schistosomiasis: The Sabin PDP and its collaborators initiated a schistosomiasis vaccine candidate Phase 1 clinical trial at the end of 2014. Schistosomiasis is a parasitic disease spread by snails that infects more than 200 million people worldwide; left untreated, the disease can cause fever, organ failure, other chronic diseases and even death. Schistosomiasis is the most deadly parasitic disease after malaria, causing approximately 200,000 deaths annually. Chagas disease: Together with domestic and international academic and industrial partners, the Sabin PDP is developing a new therapeutic vaccine to target Chagas disease, a parasitic disease that can lead to heart failure and affects approximately 10 million people, primarily in Latin America. A therapeutic vaccine is currently in the development and pre-clinical stage and we expect that a licensed vaccine would offer a number of improvements over currently available treatments. Leishmaniasis: The Sabin PDP is working to develop a vaccine to prevent cutaneous leishmaniasis, a parasitic infection transmitted by the bite of a sand fly that causes skin ulcers. The project currently is in the pre-clinical stage.Onchocerciasis Vaccine: Working through The Onchocerciasis Vaccine for Africa (TOVA) Initiative, the Sabin PDP is working to advance a pre-clinical candidate for onchocerciasis through development. Onchocerciasis is a blinding disease infecting 30 million people living near the rivers and fast-moving streams of sub-Saharan Africa.Pan-anthelminthic Vaccine: In 2013, the Sabin PDP began working to develop a pan-anthelminthic vaccine targeting three major intestinal helminth infections - ascariasis, trichuriasis and hookworm infection - which cause the highest disease burden of NTDs.Severe acute respiratory syndrome (SARS): The Sabin PDP - together with partners in the private sector, academia and the military - is working to develop and manufacture a vaccine in order to prevent potential SARS outbreaks and improve biodefense preparedness. We expect to be ready for clinical testing in 2017. 3490145 953618 Global Network for Neglected Tropical Diseases Program - The Global Network is an advocacy initiative that works in partnership with international agencies, governments, academic institutions, corporations, non-governmental development organizations and the general public to raise the awareness, political will and funding necessary to control and eliminate the seven most common neglected tropical diseases (NTDs) by 2020.The Global Network raises awareness, support and funding for programs that treat and prevent NTD infections, as well as for the integration of NTD programs into existing global health initiatives and international aid budgets.NTDs are a group of 17 parasitic and bacterial infections that impact more than 1 billion people, most of whom live on less than $1.25 per day. The Global Network focuses on the seven most common NTDs - elephantiasis, river blindness, snail fever, trachoma, hookworm, whipworm and roundworm. These diseases blind, disable and disfigure their victims, trapping them in a cycle of poverty and disease.But, for approximately 50 cents per year one person can receive treatment and protection against the seven most common NTDs, making NTD control one of the simplest and most cost-effective investments in global health and development. Since most of the pills to treat the seven most common NTDs are donated by leading pharmaceutical companies, the costs are limited to distributing medicine to the people who need them most and setting up treatment programs that communities can run themselves. 5466955 365287 Vaccine Advocacy and Education Programs - The Sabin Vaccine Institute's Vaccine Advocacy and Education program works together with leading health experts and organizations to promote awareness and increased utilization of both existing and new, underutilized vaccines. In 2014, we held various events, including a journalist information session and vaccinology course, to discuss relevant research and updates that informed public health agendas related to rotavirus, meningococcal, typhoid fever, pertussis, rubella and pneumococcal disease. The Sabin Vaccine Institute continued to be responsible for the communications and advocacy needs of the Dengue Vaccine Initiative, a global partnership to increase the priority given to dengue vaccines. The Coalition against Typhoid (CaT) is a global forum of health and immunization experts aiming to accelerate the prevention of typhoid through: the use of next generation typhoid conjugate vaccines and design of effective delivery strategies; development of improved diagnostics and coordinated surveillance; and development of improved treatment and clinical outcomes. The Sabin Vaccine Institute serves as the CaT Secretariat. The CaT objectives are accomplished through the activities of its membership. The Sustainable Immunization Financing (SIF) program operates in 12 African, and six Asian, pilot countries on advocacy-driven initiatives for sustainable immunization financing. SIF invites key stakeholders, parliamentarians, and members of ministries of health and finance to develop innovative financing solutions that sustain vital public health programs. Outputs from such meetings have ranged from declarations and ideas for tax-devoted funding to conceiving financing mechanisms, all in support of sustaining country-led immunization programs. In June 2013, Sabin launched the International Association of Immunization Managers (IAIM). This is the first-ever international association of this type. Through its membership, IAIM's goal is to help drive the achievement of national, regional and international immunization goals, including those in the Global Vaccine Action Plan (GVAP), by fostering forward-thinking and superior management of immunization programs. 17430180 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 21 0 1 70 1 0 0 0 0 0 0 0 0 0 0 X 10 8 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 MD DC NY CA FL X The Organization 2028428610 2000 Pennsylvania Avenue NW No 7100 Washington DC 20006 Morton Hyman Chairman 20.00 X X 0 0 0 Axel Hoos Interim Chairman 5.00 X X 0 0 0 Mike Whitham Secretary & Treasurer 1.00 X X 0 0 0 Baroness Helene Hayman Trustee 1.00 X 0 0 0 Paul Maddon Trustee 1.00 X 0 0 0 Michael Posner Trustee 1.00 X 0 0 0 Gary Rosenthal Trustee 1.00 X 0 0 0 Philip Russell Trustee 5.00 X 0 0 0 Marc Shapiro Trustee 1.00 X 0 0 0 Peter Thoren Trustee 1.00 X 0 0 0 Michael Marine CEO, Ex Officio Trustee 40.00 X 285484 0 11632 Peter Hotez President, Ex Offico Trustee 10.00 X 75000 0 0 Ciro de Quadros Exec VP, Ex Officio Trustee 40.00 X 185548 0 525 Jon Andrus Exec Vice President 40.00 X 50717 0 3182 Brian Davis Chief Operating Officer 40.00 X 215007 0 21721 Neeraj Mistry Program Director 40.00 X 230957 0 15568 Michael McQuestion Program Director 40.00 X 211534 0 25494 Ana Carvalho Program Director 40.00 X 164517 0 20968 Mohammed Khan Program Director 40.00 X 159305 0 18485 Marcia Lima de Souza Program Director 40.00 X 143945 0 20075 1722014 0 137650 13 0 1 0 Infectious Disease Research Institute 1616 Eastlake Ave East 400 Seattle WA 98102 Adjuvant manufacturer 413970 The George Washington University 2300 I Street NW Washington DC 20147 Clinical trial site and biostat support 394076 Center for Disease Control PO Box 15580 Atlanta GA 30333 Pertussis surveillance 183400 Fraunhofer USA Inc PO Box 673308 Detroit MI 48267 Vaccine testing and process improvements 176970 Biologics Consulting Group Inc 400 N Washington St 100 Alexandria VA 22314 Regulatory support 134403 6 1740516 17243222 4855 18983738 Membership dues 900099 16450 16450 16450 28526 28526 19028714 16450 0 28526 X 2860319 2860319 1733278 1733278 848817 664409 150562 33846 3233685 2527571 576789 129325 92552 74694 14409 3449 334896 270277 52140 12479 281007 221357 47613 12037 5768 5453 315 14328 14328 5789144 5709133 43953 36058 511259 459789 51391 79 274713 200758 69609 4346 14250 5346 8904 537695 17026 520669 801932 772685 12339 16908 1842214 1810154 31269 791 2068 1696 372 20003 20003 122932 45838 77094 Dues/subscriptions 45000 28889 9840 6271 Recruitment 21712 12790 7241 1681 Miscellaneous 20426 8718 11185 523 19407998 17430180 1720025 257793 20144024 20606134 3948788 2901182 70546 39158 164777 298928 309731 261675 68059 48056 34075 34075 24430269 23927533 2191587 2129111 204589 185303 181637 139947 2577813 2454361 X 2303747 2290427 19548709 19182745 21852456 21473172 24430269 23927533 -379284 0 X X 0 1 X 1 0 X 21076480 21900847 25314757 19979693 18983738 107255515 21076480 21900847 25314757 19979693 18983738 107255515 67492965 39762550 25207 24717 30674 24246 28526 133370 107388885 19150 0.37030 0.34010 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1217 1475 2692 19405306 19407998 1000000 250000 0 0 1000000 1000000 2000000 3000000 2130 2692 4822 250000 250000 500000 750000 719 1217 1936 309731 261675 48056 48056 Deferred rent 139947 139947 X 19114082 85368 85368 19028714 0 19028714 19493366 85368 85368 19407998 0 19407998 Part X, Line 2: Management evaluated the Institute's tax positions and concluded that the Institute's financial statements do not include any uncertain tax positions. 1 Europe (Including Iceland & Greenland) - 0 0 Grants to recipients located in region Vaccine and NTD control advocacy 492806 South America - Argentina, Bolivia, 0 0 Grants to recipients located in region Clinical trial site, NTD Control 852106 East Asia and the Pacific - 0 0 Grants to recipients located in region NTD Control 249974 Middle East and North Africa - Algeria, Bahrain, Djibouti, Egypt, 0 0 Grants to recipients located in region NTD Control 138391 0 0 0 0 0 0 1733277 0 1733277 South America Clinical trial site 753106 EFT East Asia and the Pacific NTD control 99974 EFT Middle East and North Africa NTD control 84328 EFT East Asia and the Pacific NTD control 100000 EFT Middle East and North Africa NTD control 54063 EFT South America NTD control 99000 EFT East Asia and the Pacific NTD control 50000 EFT Europe (Including Iceland & Greenland) Vaccine advocacy 365287 EFT Europe (Including Iceland & Greenland) Vaccine and NTD control advocacy 127519 EFT 8 0 0 0 0 0 0 0 Part I, Line 2: Grants are monitored in several ways. First, there is a due diligence process in awarding the grant. Second, a written and signed agreement is executed, which includes a detailed scope of work, budget and reporting requirements. Typically, payments are sent either when milestones are met or in accordance with an established payment schedule. Third, we require monthly, quarterly, and/or annual financial and technical reports from recipients prior to sending the subsequent payment. Fourth, and as needed, we conduct site visits. And finally, if deemed necessary, a third party reviews the accounting records of the recipient(s). 1 Baylor College of Medicine 1 Baylor Plaza Houston TX 77030 741613878 1466380 Vaccine Development CBM-USA 450 E Park Avenue Greenville NC 29601 362959883 159782 NTD Control INMED Partnerships for Children Inc 20110 Ashbrook Place Suite 260 Ashburn VA 20147 521482339 99978 NTD Control Pan American Health Organization 525 23rd Street NW Washington DC 20037 78956 NTD Control The George Washington University 2300 I Street NW Washington DC 20147 530196584 1055223 Vaccine Development Vaccine Development NTD Control 0 5 Part I, Line 2: Grants are monitored in several ways. First, there is a due diligence process in awarding the grant. Second, a written and signed agreement is executed, which includes a detailed scope of work, budget and reporting requirements. Typically, payments are sent either when milestones are met or in accordance with an established payment schedule. Third, we require monthly, quarterly, and/or annual financial and technical reports from recipients prior to sending the subsequent payment. Fourth, and as needed, we conduct site visits. And finally, if deemed necessary, a third party reviews the accounting records of the recipient(s). X X X X 0 0 0 0 0 0 0 0 0 Michael Marine CEO, Ex Officio Trustee 250484 0 35000 0 0 0 10000 0 1632 0 297116 0 0 0 Ciro de Quadros Exec VP, Ex Officio Trustee 140548 0 45000 0 0 0 0 0 525 0 186073 0 0 0 Brian Davis Chief Operating Officer 195007 0 20000 0 0 0 8000 0 13721 0 236728 0 0 0 Neeraj Mistry Program Director 220957 0 10000 0 0 0 0 0 15568 0 246525 0 0 0 Michael McQuestion Program Director 196534 0 15000 0 0 0 8569 0 16925 0 237028 0 0 0 Ana Carvalho Program Director 164517 0 0 0 0 0 6800 0 14168 0 185485 0 0 0 Mohammed Khan Program Director 159305 0 0 0 0 0 4267 0 14218 0 177790 0 0 0 Marcia Lima de Souza Program Director 136445 0 7500 0 0 0 5924 0 14151 0 164020 0 0 0 Form 990, Part VI, Section B, line 11 The Form 990 is prepared by an outside tax accountant based on independently audited financial statements. The Form 990 is then reviewed by the Controller and COO. Then the Form 990 is presented to the CEO and Finance Committee for their review and approval. Finally, it is presented to the full Board of Trustees for their review before filing. Form 990, Part VI, Section B, line 12c Sabin's management and Board Chair are reponsible for ensuring the conflict of interest policy is up-to-date and adhered to by the Trustees. Form 990, Part VI, Section B, line 15 Compensation of officers and/or key employees is set in consultation with input from the Board or Chair as appropriate. Sabin uses a mix of data points including: independent salary surveys; comparable pay by similar organizations; compensation firms and our own internal pay scale. Form 990, Part VI, Section C, line 19 Governing documents (upon request), conflict of interest policy (upon request), and financial statement (Sabin's website). Form 990, Part IX, line 11g Vaccine development program contract expenses: Program service expenses 3,029,726. Management and general expenses 0. Fundraising expenses 0. Total expenses 3,029,726. Transcription Service: Program service expenses 9,708. Management and general expenses 0. Fundraising expenses 0. Total expenses 9,708. Consultants: Program service expenses 1,122,530. Management and general expenses 29,032. Fundraising expenses 265. Total expenses 1,151,827. Temporary help: Program service expenses 21,051. Management and general expenses 0. Fundraising expenses 0. Total expenses 21,051. Grant subcontract: Program service expenses 1,470,291. Management and general expenses 0. Fundraising expenses 35,793. Total expenses 1,506,084. Other: Program service expenses 55,827. Management and general expenses 14,921. Fundraising expenses 0. Total expenses 70,748. Form 990, Part XII, Line 2c: The Organization has a finance committee that assumes responsibility for oversight of the audit. This process is consistent with prior years.